PHARMACY

Lazanda approved as breakthrough pain treatment

BY Alaric DeArment

BEDMINSTER, N.J. — The Food and Drug Administration has approved a drug made by Archimedes Pharma for treating breakthrough pain in cancer patients, Archimedes said last week.

Archimedes announced the approval of Lazanda (fentanyl) nasal spray for cancer patients who have acquired a tolerance to opioid drugs. Breakthrough pain is an intense, sudden pain that is unpredictable and often debilitating and occurs despite otherwise appropriate pain therapy.

“Lazanda is an important new option for patients with cancer who experience excruciating breakthrough pain,” Archimedes Pharma CEO Jeffrey Buchalter said. “Lazanda, which uses our patented PecSys drug delivery system, is designed to deliver medicine in a rapid, but controlled manner, and provides patients with an effective alternative to manage their breakthrough pain.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

APP Pharmaceuticals gets FDA OK for myxedema coma treatment

BY Allison Cerra

SCHAUMBURG, Ill. — APP Pharmaceuticals has received regulatory approval for the treatment of a complication related to hypothyroidism.

APP said that its levothyroxine sodium for injection will be marketed in single-dose 100-mcg, 200-mcg and 500-mcg vials. The drug is designed to treat myxedema coma, a life-threatening complication of hypothyroidism.

“APP worked closely with the FDA to secure approval of levothyroxine sodium for injection because of the expressed medical need for this drug,” APP Pharmaceuticals president and CEO John Ducker said. “We will continue to collaborate with the FDA to gain approval of established and much-needed drugs that maintain the highest standards of quality, safety and efficacy.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Collis succeeds Yost as CEO of AmerisourceBergen

BY Michael Johnsen

VALLEY FORGE, Pa. — David Yost officially handed the reins of AmerisourceBergen to Steven Collis, who was named president and CEO on Friday, as Yost prepares for retirement.

"On behalf of our entire company, I thank Dave for his 37 years of extraordinary service to AmerisourceBergen, and for his gracious support during the leadership transition," Collis stated. "I believe with our momentum, our position in growing markets, our talented and seasoned management team, and our dedication to efficiency and innovative customer service, we will continue to drive success by growing our business and providing value to our customers, suppliers, shareholders and our associates."

Collis previously served as president and COO, responsible for all AmerisourceBergen business units, including AmerisourceBergen Drug Corp., AmerisourceBergen Specialty Group, AmerisourceBergen Consulting Services and AmerisourceBergen Packaging Group. Before being promoted to that position in November 2010, Collis was AmerisourceBergen EVP and president of ABDC, the company’s largest subsidiary with revenues of more than $60 billion.

keyboard_arrow_downCOMMENTS

Leave a Reply

D.DEMII says:
Nov-19-2012 02:23 am

Fully agree with your points here. All the posts are fully informative and having very good themes. I love to visit your blog again and again its really increase my knowledge. Thanks for the awesome post. Pakistan Fashion Events

N.OYOLA says:
Jul-05-2011 12:16 pm

Congratulations! Nilda L. Oyola National Sales and Marketing Manager Majestic Drug Co., Inc.

TRENDING STORIES